Technical Data
S5620-01G
Sprouty 1 (hSPRY1, Sprouty Homolog 1 Antagonist of FGF Signaling, Protein Sprouty Homolog 1, Sprouty Homolog 1, SPRY1, Spry-1)
Description:
SPRY1 is a 34-38kD member of the sprouty family of proteins. It is widely expressed, being found in multiple embryonic and adult tissues. SPRY1 is considered a negative regulator of cellular signaling. In particular, it appears to both inhibit MAP kinase signaling following RTK activation, and block TCR signaling following antigen activation. It interacts with a number of molecules, including PLC-g 1, LAT, CBL, caveolin-1 and SPRY2. Human SPRY1 is 319aa in length. It contains one CBL-TKB binding site aa51-57 that is phosphorylated at Tyr53, a Ser-rich region aa112-131, and a Cys-rich domain aa181-306 that mediates intracellular translocation. SPRY1 undergoes serine phosphorylation, ubiquitination and palmitoylation, the latter which induces SPRY1 to associate with cell membranes. Over aa1-178, human SPRY1 shares 76% aa identity with mouse SPRY1.

Applications:
Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 1:16,000
Western Blot: 1-3ug/ml
Immunohistochemistry (Paraffin): 1-3ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to CPSRGQGKPS, from SPRY1, at C-terminal (NP_005832.1, NP_955359.1).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in Tris saline, 0.02% sodium azide, pH 7.3, 0.5% BSA.
Specificity:
Recognizes human SPRY1. Species Crossreactivity: Mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, Kool M. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res. 2010 Jan 15;70(2):762-71. Epub 2010 Jan 12.